Table 3.
Correlation between EGR1 expression with the clinical baseline characteristics of patients with LC
| Clinical characteristics | EGR1 |
p | ||
|---|---|---|---|---|
| High | Low | |||
| Age | ≤ 65 | 11 | 9 | > 0.05 |
| > 65 | 13 | 10 | ||
| Sex | Female | 14 | 12 | > 0.05 |
| Male | 10 | 7 | ||
| Size (cm) | ≤ 4 | 6 | 10 | < 0.05 |
| > 4 | 18 | 9 | ||
| TNM stage | I-II | 7 | 13 | < 0.05 |
| III-IV | 17 | 6 | ||
| TBIL (mg/dL) | 1.56 ± 0.36 | 0.62 ± 0.25 | < 0.05 | |
| AST (IU/L) | 185.69 ± 32.17 | 102.75 ± 23.74 | < 0.05 | |
| ALT (IU/L) | 95.71 ± 16.72 | 47.56 ± 7.42 | < 0.05 | |
| AFP (U/L) | 281.52 ± 62.15 | 192.71 ± 31.57 | < 0.05 | |
Note: EGR1, early growth response 1; LC, liver cancer; TNM, tumor node metastasis; TBIL, total bilirubin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; AFP, alpha-fetoprotein